Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C

Trial Profile

Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs AAV1-gSG (Primary)
  • Indications Limb girdle muscular dystrophies; Sarcoglycanopathies
  • Focus Adverse reactions
  • Sponsors Genethon
  • Most Recent Events

    • 05 May 2014 tidied drug term in text and treatment table
    • 22 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top